Johnson & Johnson COVID-19 vaccine candidate moves forward to phase 3
Johnson & Johnson today said that its COVID-19 vaccine candidate is moving to a global phase 3 clinical trial.
The JNJ-78436735 vaccine candidate, which was developed by J&J subsidiary Janssen Pharmaceutical Companies, will be administered to 60,000 volunteers at 215 clinical sites across three continents. The vaccine is believed to be the first COVID-19 candidate that would require just a single dose to spur immunity in patients.
The trial will be funded by Johnson & Johnson/Janssen, the National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…